Haemophilia A management with emicizumab: A survey of haematologists in the United States

Anisha M. Patel; Wendy E. Owens; Kathleen Poulos; Karina Raimundo; Gabriel Wong; Janet Bernard; Janet Powers; Richard H. Ko

doi:10.2478/jhp-2021-0017

Abstract

Abstract Background

Emicizumab is a bispecific monoclonal antibody approved in the United States (US) for the treatment of people with haemophilia A (PwHA) with or without factor VIII (FVIII) inhibitors. Changes to haematologists’ practices since the approval of emicizumab are of interest to the haemophilia A community.

Aim

To identify the clinical characteristics of PwHA receiving emicizumab (PwHArE) in the real-world setting and gain insight into the disease management practices of haematologists treating PwHArE.

Methods

In total, 50 haematologists across the US completed a one-time, 30-minute, online, qualitative survey consisting of 55 questions (including 11 screening questions) in May 2019. Haematologists were required to be board-certified in haematology, practising in the US, ≥2 years post-residency experience, and currently treating ≥3 PwHA with emicizumab.

Results

Haematologists reported their PwHArE were mostly adults (aged ≥18 years; 66%) with severe phenotypes (66%), with and without FVIII inhibitors. Haematologists perceived that PwHArE had similar or better treatment adherence (40% and 50%, respectively) compared with PwHA on other treatments, sought the same or lower levels of routine care (72% and 14%, respectively), and were similarly or more physically active (52% and 32%, respectively). Additionally, most haematologists currently using immune tolerance induction (ITI) in PwHArE reported using lower doses of FVIII (73%) and shorter durations (45%) for ITI.

Conclusions

Availability of emicizumab has resulted in changes in the care of PwHArE, including bleed management, FVIII monitoring, activity guidance, surgery, and use of ITI. Understanding patterns of disease management can inform clinical care.

Article

View Full Article

References

1. Mannucci PM, Tuddenham EG. The hemophilias--from royal genes to gene therapy. N Engl J Med 2001; 344(23): 1773–9. doi: https://doi.org/10.1056/nejm200106073442307.
2. Srivastava A, Santagostino E, Dougall A, et al. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia 2020; 26 (Suppl 6): 1–158. doi: https://doi.org/10.1111/hae.14046.
3. Knobe K, Berntorp E. Haemophilia and joint disease: pathophysiology, evaluation, and management. J Comorb 2011; 1: 51–9. doi: https://doi.org/10.15256/joc.2011.1.2.
4. Oldenburg J, Shima M, Kruse-Jarres R, et al. Outcomes in children with hemophilia A with inhibitors: Results from a noninterventional study. Ped Blood Cancer 2020; 67: e28474. doi: https://doi.org/10.1002/pbc.28474.
5. Witkop M, Neff A, Buckner TW, et al. Self-reported prevalence, description and management of pain in adults with haemophilia: methods, demographics and results from the Pain, Functional Impairment, and Quality of life (P-FiQ) study. Haemophilia 2017; 23(4): 556–65. doi: https://doi.org/10.1111/hae.13214.
6. Manco-Johnson MJ, Lundin B, Funk S, et al. Effect of late prophylaxis in hemophilia on joint status: a randomized trial. J Thromb Haemost 2017; 15(11)2115–24. doi: https://doi.org/10.1111/jth.13811.
7. Franchini M. The modern treatment of haemophilia: a narrative review. Blood Transfus 2013; 11(2): 178–82. doi: https://doi.org/10.2450/2012.0166-11.
8. Lambert T, Benson G, Dolan G, et al. Practical aspects of extended half-life products for the treatment of haemophilia. Ther Adv Hematol 2018; 9(9): 295–308. doi: https://doi.org/10.1177/2040620718796429.
9. Thornburg CD, Duncan NA. Treatment adherence in hemophilia. Patient Prefer Adherence 2017; 11: 1677–86. doi: https://doi.org/10.2147/PPA.S139851.
10. Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia 2003; 9(4): 418–35. doi: https://doi.org/10.1046/j.1365-2516.2003.00780.x.
11. Shapiro AD, Mitchell IS, Nasr S. The future of bypassing agents for hemophilia with inhibitors in the era of novel agents. J Thromb Haemost 2018; 16(12): 2362–74. doi: https://doi.org/10.1111/jth.14296.
12. Lacroix-Desmazes S, Voorberg J, Lillicrap D, Scott DW, Pratt KP. Tolerating factor VIII: Recent progress. Front Immunol 2019; 10: 2991. doi: https://doi.org/10.3389/fimmu.2019.02991.
13. Carcao M, Escuriola-Ettingshausen C, Santagostino E, et al. The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab. Haemophilia 2019; 25(4): 676–84. doi: https://doi.org/10.1111/hae.13762.
14. Kitazawa T, Igawa T, Sampei Z, et al. A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. Nat Med 2012; 18(10): 1570–4. doi: https://doi.org/10.1038/nm.2942.
15. Oldenburg J, Mahlangu JN, Kim B, et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med 2017; 377(9): 809–18. doi: https://doi.org/10.1056/NEJMoa1703068.
16. Mahlangu J, Oldenburg J, Paz-Priel I, et al. Emicizumab prophylaxis in patients who have hemophilia A without inhibitors. N Engl J Med 2018; 379(9): 811–22. doi: https://doi.org/10.1056/NEJMoa1803550.
17. Pipe SW, Shima M, Lehle M, et al. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study. Lancet Haematol 2019; 6(6): E295–E305. doi: https://doi.org/10.1016/S2352-3026(19)30054-7.
18. Young G, Liesner R, Chang T, et al. A multicenter, open-label, phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors. Blood 2019; 134(24): 2127–38. doi: https://doi.org/10.1182/blood.2019001869.
19. US Food and Drug Administration. HEMLIBRA^® (emicizumabkxwh) injection for subcutaneous use, prescribing information [Initial U.S. approval: 2017] 2018. Available from: https://www.gene.com/download/pdf/hemlibra_prescribing.pdf (accessed August 2021).
20. Kitazawa T, Esaki K, Tachibana T, et al. Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa, emicizumab, depends on its ability to bridge the antigens. Thromb Haemost 2017; 117(7): 1348–57. doi: https://doi.org/10.1160/th17-01-0030.
21. Callaghan M, Negrier C, Paz-Priel I, et al. Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1–4 studies. Blood 2021; 137(16): 2231–42. doi: https://doi.org/10.1182/blood.2020009217.
22. Schmitt C, Adamkewicz JI, Xu J, et al. Pharmacokinetics and pharmacodynamics of emicizumab in persons with hemophilia A with factor VIII inhibitors: HAVEN 1 study. Thromb Haemost 2021; 121(3): 351–60. doi: https://doi.org/10.1055/s-0040-1717114.
23. Batsuli G, Zimowski KL, Tickle K, Meeks SL, Sidonio RF, Jr. Immune tolerance induction in paediatric patients with haemophilia A and inhibitors receiving emicizumab prophylaxis. Haemophilia 2019; 25(5): 789–96. doi: https://doi.org/10.1111/hae.13819.
24. Batsuli G, Greene A, Meeks SL, Sidonio Jr RF. Emicizumab in tolerized patients with hemophilia A with inhibitors: A single-institution pediatric cohort assessing inhibitor status. Res Pract Thromb Haemost 2021; 5(2): 342–8. doi: https://doi.org/10.1002/rth2.12475.
25. Oldenburg J, Mahlangu JN, Bujan W, et al. The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study. Haemophilia 2019; 25(1): 33–44. doi: https://doi.org/10.1111/hae.13618.
26. Mancuso ME, Mahlangu J, Sidonio Jr R, et al. Health-related quality of life and caregiver burden of emicizumab in children with haemophilia A and factor VIII inhibitors—Results from the HAVEN 2 study. Haemophilia 2020; 26(6): 1009–18. doi: https://doi.org/10.1111/hae.14183.
27. Skinner MW, Negrier C, Paz-Priel I, et al. The effect of emicizumab prophylaxis on long-term, self-reported physical health in persons with haemophilia A without Factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies. Haemophilia 2021; 27(5): 854–65. doi: https://doi.org/10.1111/hae.14363.
28. Parnes A, Mahlangu, JN., Pipe, SW., Paz-Priel, I., Lehle, M., Trask, PC., Jiménez-Yuster, V. Patient preference for emicizumab versus prior factor therapy in persons with haemophilia A: results from the HAVEN 3 and HAVEN 4 studies. Haemophilia 2021. doi: https://doi.org/10.1111/hae.14421.
29. Jiménez-Yuste V, Peyvandi F, Klamroth R, et al. Final Analysis of the STASEY Trial: A Single-arm, Multicenter, Open-label, Phase III Clinical Trial Evaluating the Safety and Tolerability of Emicizumab Prophylaxis in Persons with Hemophilia A (PwHA) with Factor (F)VIII Inhibitors [abstract]. Res Pract Thromb Haemost 2021; 5(2). Available from https://abstracts.isth.org/abstract/final-analysis-of-the-stasey-trial-a-single-armmulticenter-open-label-phase-iii-clinical-trial-evaluating-the-safety-and-tolerability-of-emicizumab-prophylaxis-in-persons-with-hemophilia-a-pwha/ (accessed December 2021).
30. McCary I, Guelcher C, Kuhn J, et al. Real-world use of emicizumab in patients with haemophilia A: Bleeding outcomes and surgical procedures. Haemophilia 2020; 26(4): 631–6. doi: https://doi.org/10.1111/hae.14005.
31. Barg AA, Livnat T, Budnik I, et al. Emicizumab treatment and monitoring in a paediatric cohort: real-world data. Br J Haematol 2020; 191(2): 282–90. doi: https://doi.org/10.1111/bjh.16964.
32. Ebbert PT, Xavier F, Seaman CD, Ragni MV. Emicizumab prophylaxis in patients with haemophilia A with and without inhibitors. Haemophilia 2020; 26: 41–6. doi: https://doi.org/10.1111/hae.13877.
33. Lenting PJ. Laboratory monitoring of hemophilia A treatments: new challenges. Blood Adv 2020; 4(9): 2111–8. doi: https://doi.org/10.1182/bloodadvances.2019000849.
34. Santagostino E, Oldenburg J, Chang T, et al.. Surgical experience from four phase III studies (HAVEN 1–4) of emicizumab in persons with haemophilia A (PwHA) with or without FVIII inhibitors. ISTH; 2019; Melbourne, Australia. Available from https://www.emicizumabinfo.com/content/dam/gene/emicizumabinfo/pdf/presentations/isth-2019-oral-haven-surgeries-santagostino.pdf (accessed December 2021).
35. Nuss R, Hedegaard H, Riske B, et al. Medical care for haemophilia. Haemophilia 1998; 4: 1365–2516. doi: https://doi.org/10.1046/j.1365-2516.1998.00196.x.
36. Royal S, Schramm W, Berntorp E, et al. Quality-of-life differences between prophylactic and on-demand factor replacement therapy in European haemophilia patients. Haemophilia 2002; 8(1): 44–50. doi: https://doi.org/10.1046/j.1365-2516.2002.00581.x.
37. Garcia-Dasi M, Aznar JA, Jimenez-Yuste V, et al. Adherence to prophylaxis and quality of life in children and adolescents with severe haemophilia A. Haemophilia 2015; 21(4): 458–64. doi: https://doi.org/10.1111/hae.12618.
38. Patel AM, Corman SL, Chaplin S, Raimundo K, Sidonio RF. Economic impact model of delayed inhibitor development in patients with hemophilia a receiving emicizumab for the prevention of bleeding events. J Med Econ 2019; 22(12): 1328–37. doi: https://doi.org/10.1080/13696998.2019.1669614.
39. Cortesi PA, Castaman G, Trifirò G, et al. Cost-effectiveness and budget impact of emicizumab prophylaxis in haemophilia A patients with inhibitors. Thromb Haemost 2020; 120(02): 216–28. doi: https://doi.org/10.1055/s-0039-3401822.
40. Zhou ZY, Raimundo K, Patel AM, et al. Model of short- and long-term outcomes of emicizumab prophylaxis treatment for persons with hemophilia A. J Manag Care Spec Pharm 2020; 26(9): 1109–20. doi: https://doi.org/10.18553/jmcp.2020.19406.
41. Lin P-C, Liao Y-M, Tsai S-P, Chang T-T. Immune tolerance induction therapy for patients with hemophilia A and FVIII inhibitors particularly using low-dose regimens. Pediatr Blood Cancer 2011; 57: 1029–33. doi: https://doi.org/10.1002/pbc.23291.
42. Institute for Clinical and Economic Review; New England Comparative Effectiveness Public Advisory Council. Emicizumab for hemophilia A with inhibitors: effectiveness and value. Final evidence report. [Boston, Mass.]: ICER: April 16, 2018. Available from https://collections.nlm.nih.gov/catalog/nlm:nlmuid-101744955-pdf (accessed December 2021).
43. Institute for Clinical and Economic Review; New England Comparative Effectiveness Public Advisory Council. Valoctocogene roaparvovec and emicizumab for hemophilia A: effectiveness and value. Final report. [Boston, Mass.]: ICER, November 20; 2020. Available from https://icer.org/wp-content/uploads/2020/10/ICER_Hemophilia-A_Final-Report_112020.pdf (accessed December 2021).
44. Kelley K, CLark B, Brown V, Sitzia J. Good practice in the conduct and reporting of survey research. Int J Qual Health Care 2003; 15(3): 261–6. doi: https://doi.org/10.1093/intqhc/mzg03

PDF Download

Download PDF

Open in full-page viewer

Authors

Anisha M. Patel

patel.anisha@gene.com

Genentech, Inc., South San Francisco, CA, USA
Wendy E. Owens

Genentech, Inc., South San Francisco, CA, USA
Kathleen Poulos

MedPanel, Waltham, MA, USA ; New affiliation: Ferrum Health, Inc., San Francisco, CA, USA
Karina Raimundo

Genentech, Inc., South San Francisco, CA, USA
Gabriel Wong

Genentech, Inc., South San Francisco, CA, USA ; New affiliation: Seagen Inc., San Francisco, CA, USA
Janet Bernard

JANET BERNARD MedPanel, Waltham, MA, USA
Janet Powers

MedPanel, Waltham, MA, USA
Richard H. Ko

Genentech, Inc., South San Francisco, CA, USA